ConTiPi Medical

ConTIPI Medical develops noninvasive and disposable vaginal devices for women with pelvic floor disorders such as stress urinary incontinence and pelvic organ prolapse. The company's devices are inserted vaginally using a disposable applicator, then open to provide support to predefined vaginal walls. For removal and disposal, a pull of the attached string collapses the device into its original size. One of the company's first devices, for the management of stress urinary incontinence in women, was sold to Kimberly Clark Worldwide Inc. and is now marketed in North America under the name Poise Impressa. ConTIPI Medical also offers ProVate, a ring pessary solution designed for pelvic organ prolapse. The device is inserted by the user in its small form, then enlarges into a ring of up to 91 millimeters. After up to seven days of use, a pull of the string collapses the ring back into its tiny dimensions for removal and disposal. ProVate has a 510(k) clearance from FDA for marketing in the United States, and a CE Mark for marketing in the EU. The ProVate Device is ready for the market, and ConTIPI Medical hired Bourne Partners (Charlotte, NC, United States) as its mergers and acquisitions advisor.

ConTiPi Medical has raised $11M in total funding across 2 rounds. The company is currently at the A stage. Key investors include Capital Point, Zeev Bronfeld, Boris Krasny.

ConTiPi Medical was founded in 2014 by Elan Ziv (Founder, CEO & Medical Director).

ConTiPi Medical operates in Health Tech & Life Sciences, Medical Devices, Medical Treatment & Therapeutics. Target customers: Healthcare & Life Sciences, Healthcare, Providers, Consumers, Demographics & Family, Women.

ConTiPi Medical is based in Alon ha-Tavor St 2, Caesarea, Israel, Center District.